PARP Inhibitor Market, By Drug (Lynparza, Niraparib, Rucaparib and Others), By Indication (Ovarian cancer, Breast cancer, Prostate cancer, Lung cancer and Others), By Distribution Channel (Hospital pharmacies, Online pharmacies and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

PARP Inhibitor Market was valued at US$ 12.5 billion in 2024 and is projected to grow at a CAGR of 18.3% to reach US$ 67.0 billion by 2034.

As cancer turns aggressive in nature, it is prone to attack other parts of the body. An increase in the number of aggressive cancer cases has poised cancer treatment as a challenge for the healthcare industry.  Variety of cancer treatment methods are being employed, such as surgery, chemotherapy, PARP inhibitor and radiation therapy. PARP inhibitors are used to treat many heritable cancers. These inhibitors depend on PARP cells rather than regular cells and are attractive target for cancer therapy. Chemotherapy and radiation therapy attempt to kill cancer cells by inducing high levels of DNA damage. By inhibiting PARP1 DNA repair, the effectiveness of these therapies can be increased. BRCA1, BRCA2 and PALB2 are proteins that are important for the repair of double-strand DNA breaks by the error-free homologous recombinational repair, or HRR, pathway. When the gene for one of these proteins is mutated, the change can lead to errors in DNA repair that can eventually cause breast cancer. When subjected to enough damage at one time, the altered gene can cause the death of the cells. PARP1 is a protein that is important for repairing single-strand breaks.

Impact of Covid-19 pandemic on market

Number of patients suffering from cancer is rising day by day. Due to closing of research labs and a break in the supply chain, the market of PARP inhibitor has suffered a setback. This report will quantify the impact of this pandemic on the market.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Rising prevalence of cancer patients

The National Cancer Institute reports that more than 60% of the world’s new cancer cases occur in Africa, Asia, and Central and South America; 70% of the world’s cancer deaths also occur in these regions. The International Agency for Research on Cancer (IARC) predicts that by 2030, the global burden is expected to rise to 21.7 million new cancer cases and 13 million cancer deaths, simply due to growth and aging of population, leaving aside factors, such as smoking, poor diet, physical inactivity, and fewer childbirths in economically developing countries which boost the market of PARP inhibitor.

High demand for PARP inhibitor for ovarian cancer

Ovarian cancer held a major market position for PARP inhibitors which boost the market. PARP inhibitors have ability to help repair damaged DNA and hence becoming increasingly useful tool for various treatments for cancers which drives the market. Several PARP inhibitors are in last-stage pipeline, thus creating positive growth factors for this market.

However, technical and clinical-related challenges might hamper growth of the global market to a certain extent.

The PARP inhibitor market is segmented based on drug, indication, distribution channel, and region.

On the basis of drug, the global PARP inhibitor market is segmented into lynparza, niraparib, rucaparib and others. Based on indication, the target market is segmented into ovarian cancer, breast cancer, prostate cancer, lung cancer and others. On the basis of distribution channel, the target market is segmented into hospital pharmacies, online pharmacies and others.

Regional Insights:

On region, the PARP inhibitor market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads the market of PARP inhibitor market due to increasing aging population and prevalence of large number of diseases. Further, presence of key players and advancement in technologies are the driving factor for this region.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the PARP Inhibitor Market report based on Drud, indication, distribution channel and region:

PARP inhibitor market, By Region:

• North America
  • Rest of Middle East & Africa
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • • U.S.
    • Canada

The key players operating in the PARP inhibitor market includes AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Jiangsu Hengrui Medicine Co., Ltd, Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc. Companies are continuously rising the production and supply of drugs to grow this market.

• Genentech, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• AstraZeneca Plc.
•  Johnson & Johnson
•  GlaxoSmithKline plc.
•  Pfizer Inc.
•  Jiangsu Hengrui Medicine Co. Ltd
•  Clovis Oncology Inc.
•  AbbVie Inc.
• Bristol - Myers Squibb
• Merck KGaA

 “*” marked represents similar segmentation in other categories in the respective section